Promal Methallylescaline 21 MG Pellets

Promal Methallylescaline 21 MG Pellets

Promal Methallylescaline (MAL) is a synthetic psychedelic compound of the phenethylamine class, structurally related to mescaline. Each pellet contains a precise dose of 21 mg of Methallylescaline, packaged in a user-friendly blister format for research purposes. The compound has the chemical formula C₁₃H₁₉NO₃ and a molecular weight of 237.30 g/mol. It acts primarily as an agonist of serotonin receptors (particularly 5-HT₂ₐ), leading to altered states of consciousness, sensory enhancement, and visual hallucinations.

Applications of use

• Scientific research: Study of cognitive functions, perception changes and therapeutic potential (e.g. for anxiety, depression or PTSD).

• Sensory studies: Research into visual/auditory hallucinations and synesthesia-like effects.

• Pharmacological analysis: Mechanism research via receptor interactions (serotonin agonism).

Disadvantages and Risks

• Physical side effects: Nausea, vomiting, increased heart rate and blood pressure.

• Psychological effects: Anxiety, paranoia and emotional overstimulation, especially at high doses (>60 mg).

• Security risks: Not for human consumption; strict laboratory use required.

Instructions for use

Dosage and protocol:

• Threshold dose: 10–20 mg

• Light dose: 20–40 mg

• Standard dose: 40–60 mg

• High dose: >60 mg (for experienced researchers only).
  Laboratory guidelines:

1. Use precision weighing equipment and personal protective equipment (gloves, safety glasses).

2. Conduct experiments in controlled environments with ventilation and emergency protocols.

3. Start with low doses and increase gradually based on research results.

Frequently Asked Questions (FAQ's)

1. Is this product legal?
Promal Methallylescaline is for scientific research use only and is subject to local research chemical regulations. Always check regional regulations.

2. How long do the effects last?
Effects last 8–12 hours, longer than traditional psychedelics.

3. Can it be used therapeutically?
Research focuses on mental health potential, but clinical applications are not approved.

Lab Report and Recommended Scenarios

Pharmacological characteristics (based on receptor studies):

• Receptor binding affinity: High for 5-HT₂ₐ receptors (Ki<50K_i < 50Ki<50 nM), moderate for TAAR₁ receptors (Ki=1,900–3,900K_i = 1,900–3,900Ki=1,900–3,900 nM).

• Documented effects:

  • Visual distortions and sensory enhancement at 20–40 mg.

  • Ego dissolution and cognitive shifts at >60 mg.

Recommended research scenarios:

• Perception studies: Doses of 20–40 mg for sensory processing analysis.

• Therapeutic exploration: Low doses (10–20 mg) for mood modulation research.

• Comparative pharmacology: Combination with receptor antagonists to isolate mechanisms.

Summary

Promal Methallylescaline 21 MG Pellets provide a standardized model for psychedelic research, with an emphasis on receptor interactions and cognitive effects. Risks such as cardiovascular stress and psychological side effects require strict protocol adherence. Dosage should be tailored to research goals, with low doses appropriate for initial research and higher doses for advanced studies.